Meanwhile, immune-related adverse events were frequently reported with PD-1/PD-L1 inhibitors, including rash, pruritus, colitis, aspartate aminotransferase elevation and hypothyroidism [9,58]. This evidence concerns the gene RPL17 and hypothyroidism.